Respiratory Test Kit QuickVue® At-Home OTC COVID-19 Test 25 Tests CLIA Waived

Features

• For Use Under an Emergency Use Authorization (EUA) Only: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
• Product ships with minimum 30 days dating
• The QuickVue At-Home OTC COVID-19 Test is intended for the qualitative detection of nucleocapsid proteins from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 36 hours between tests
• This test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal(NS) swab specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals aged 2 years or older
• Positive results indicate the presence of virus-specific proteins, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status
• Positive results do not rule out bacterial infection or co-infection with other viruses and the agent detected may not be the definite cause of disease. Individuals who test positive with the QuickVue At-Home OTC COVID-19 Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary
• Negative results should be treated as presumptive, do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions
• Negative results should be considered in the context of an individual’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management
• Individuals should provide all results obtained with this product to their healthcare provider for public health reporting
• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens
• The test is intended to be read at 10 minutes; If the test is read before this or is read more than 5 minutes after the indicated read time, results may be inaccurate and the test should be repeated
• In the event of resale: Strict adherence to the adherence to the Conditions Related to Printed Materials, Advertising and Promotion contained in the Emergency Use Authorization (EUA) is required; o Minimum Advertised Price of $24.95 must be used

More Information

• QuickVue At-Home OTC COVID-19 Test FDA EUA Letter
• QuickVue At-Home OTC COVID-19 Test Fact Sheet
• QuickVue At-Home OTC COVID-19 Test Healthcare Providers Fact Sheet
• QuickVue At-Home OTC COVID-19 Test Patients Fact Sheet
• QuickVue At-Home OTC COVID-19 Healthcare Provider IFU
• Quidel Quick Vue At-Home OTC COVID-19 Test Dating Extension Letter
• QuickVue At-Home OTC COVID-19 Test User Instructions
• Quidel 12.28.21 Omicron Variant Letter